Physicians' Academy for Cardiovascular Education

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

Video navigation menu

  • The PCSK9 story adds a new chapter to LDL-lowering: lower for longer 00:23
  • FOURIER: further LDL lowering achieved risk reductions significant for patient care 01:02
  • What are the differences between FOURIER and SPIRE?  01:48
  • Comparing event reductions in SPIRE and FOURIER 02:26
  • Take-home messages from FOURIER and SPIRE 02:56
  • Whom to give PCSK9 inhibitors? 03:19

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Paul M. Ridker, MD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Funding

Funding was provided by an unrestricted educational grant from Amgen